國立高雄大學圖資館 |

語系: 繁體中文

說明(常見問題)

圖資館首頁

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Immunotherapy of canceran innovative...

SpringerLink (Online service)

Immunotherapy of canceran innovative treatment comes of age /

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Immunotherapy of canceredited by Yoshiyuki Yamaguchi.
其他題名:	an innovative treatment comes of age /
其他作者:	Yamaguchi, Yoshiyuki.
出版者:	Tokyo :Springer Japan :2016.
面頁冊數:	ix, 358 p. :ill., digital ;24 cm.
Contained By:	Springer eBooks
標題:	CancerImmunotherapy.
電子資源:	http://dx.doi.org/10.1007/978-4-431-55031-0
ISBN:	9784431550310$q(electronic bk.)

Immunotherapy of canceran innovative treatment comes of age /
Immunotherapy of canceran innovative treatment comes of age /[electronic resource] :edited by Yoshiyuki Yamaguchi. - Tokyo :Springer Japan :2016. - ix, 358 p. :ill., digital ;24 cm.

Part I Overview, History, Classification -- Chapter 1 Overview of Current Cancer Immunotherapy -- Part II BRMs and Crude Agents -- Chapter 2 Bacterial Preparations -- Chapter 3 Polysaccharides -- Chapter 4 BCG -- Part III Cytokines -- Chapter 5 αβ-T Cells -- Chapter 6 NKT Cell-Based Immunotherapy -- Chapter 7 Natural Killer Cells -- Chapter 8 γδ T Cell-Based Cancer Immunotherapy -- Chapter 9 Genetically engineered T cells -- Part IV Vaccine Therapy -- Chapter 10 Peptide Vaccine -- Chapter 11 Personalized Peptide Vaccine -- Chapter 12 WT1 Peptide Vaccine for the Treatment of Malignancies -- Chapter 13 Protein vaccine -- Chapter 14 Dendritic Cell-Based Vaccine for Cancer -- Part V Immunoadjuvants -- Chapter 15 CpG Motif -- Chapter 16 Pattern Recognition by Dendritic Cells and Its Application to Vaccine Adjuvant for Antitumor Immunotherapy -- Chapter 17 Novel Adjuvants -- Part VI Immunocheckpoints -- Chapter 18 Anti-CTLA-4 Ab -- Chapter 19 Anti-PD-1, PD-L1 Ab -- Chapter 20 Novel Targets of Immune Inhibitory and Stimulatory Co-signals -- Part VII Regulation of Immunosuppression -- Chapter 21 Regulatory T Cells -- Chapter 22 MDSC: Myeloid-Derived Suppressor Cells -- Part VIII Immune-Related Response Criteria and Guidance for Clinical Trials -- Chapter 23 Immune-Related Response Criteria and Guidance for Clinical Trials -- Part IX Personalized Immunotherapy -- Chapter 24 ersonalized cancer immunotherapy: Immune biomarkers and combination immunotherapy.

This timely book, published just as cancer immunotherapy comes of age, summarizes the rationale, present status, and future perspective for cancer immunotherapy. Included are explanations of the constitution of the immune system and immunocheckpoints, the mechanism of antigen presentation and recognition, valuable modalities, clinical trials and guidance, personalization, and biomarkers, all of which are essential for understanding the success of cancer immunotherapy. This innovative therapy has been investigated worldwide as the fourth line of cancer treatment after the standard treatments of surgery, chemotherapy, and radiotherapy. The progress in fundamental understanding of tumor immunology and the recent advances in clinical trials have opened new avenues with a cancer vaccine in 2010 and immunocheckpoint modulation in 2011, with their approval already granted in the United States. Today, there are no doubts, even among experts in cancer chemotherapy and radiotherapy, that the immune system plays a vital role in tumor eradication. Following American approval, many clinical trials of cancer immunotherapy are being conducted. With this book the reader will readily understand the paradigm shift in cancer treatment and will realize the importance of cancer immunotherapy. The great value of immunotherapy will be obvious, not only for tumor shrinkage but for prolonging patient survival.

ISBN: 9784431550310$q(electronic bk.)

Standard No.: 10.1007/978-4-431-55031-0doiSubjects--Topical Terms:

201873
Cancer
--Immunotherapy.

LC Class. No.: RC271.I45

Dewey Class. No.: 616.99406

Immunotherapy of canceran innovative treatment comes of age /
LDR:03828nmm a2200313 a 4500 001 483511
003 DE-He213
005 20160822105833.0
006 m d
007 cr nn 008maaau
008 161007s2016 ja s 0 eng d
020 $a 9784431550310$q(electronic bk.)
020 $a 9784431550303$q(paper)
024 7 $a 10.1007/978-4-431-55031-0 $2 doi
035 $a 978-4-431-55031-0
040 $a GP $c GP
041 0 $a eng
050 4 $a RC271.I45
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
082 0 4 $a 616.99406 $2 23
090 $a RC271.I45 $b I33 2016
245 0 0 $a Immunotherapy of cancer $h [electronic resource] : $b an innovative treatment comes of age / $c edited by Yoshiyuki Yamaguchi.
260 $a Tokyo : $b Springer Japan : $b Imprint: Springer, $c 2016.
300 $a ix, 358 p. : $b ill., digital ; $c 24 cm.
505 0 $a Part I Overview, History, Classification -- Chapter 1 Overview of Current Cancer Immunotherapy -- Part II BRMs and Crude Agents -- Chapter 2 Bacterial Preparations -- Chapter 3 Polysaccharides -- Chapter 4 BCG -- Part III Cytokines -- Chapter 5 αβ-T Cells -- Chapter 6 NKT Cell-Based Immunotherapy -- Chapter 7 Natural Killer Cells -- Chapter 8 γδ T Cell-Based Cancer Immunotherapy -- Chapter 9 Genetically engineered T cells -- Part IV Vaccine Therapy -- Chapter 10 Peptide Vaccine -- Chapter 11 Personalized Peptide Vaccine -- Chapter 12 WT1 Peptide Vaccine for the Treatment of Malignancies -- Chapter 13 Protein vaccine -- Chapter 14 Dendritic Cell-Based Vaccine for Cancer -- Part V Immunoadjuvants -- Chapter 15 CpG Motif -- Chapter 16 Pattern Recognition by Dendritic Cells and Its Application to Vaccine Adjuvant for Antitumor Immunotherapy -- Chapter 17 Novel Adjuvants -- Part VI Immunocheckpoints -- Chapter 18 Anti-CTLA-4 Ab -- Chapter 19 Anti-PD-1, PD-L1 Ab -- Chapter 20 Novel Targets of Immune Inhibitory and Stimulatory Co-signals -- Part VII Regulation of Immunosuppression -- Chapter 21 Regulatory T Cells -- Chapter 22 MDSC: Myeloid-Derived Suppressor Cells -- Part VIII Immune-Related Response Criteria and Guidance for Clinical Trials -- Chapter 23 Immune-Related Response Criteria and Guidance for Clinical Trials -- Part IX Personalized Immunotherapy -- Chapter 24 ersonalized cancer immunotherapy: Immune biomarkers and combination immunotherapy.
520 $a This timely book, published just as cancer immunotherapy comes of age, summarizes the rationale, present status, and future perspective for cancer immunotherapy. Included are explanations of the constitution of the immune system and immunocheckpoints, the mechanism of antigen presentation and recognition, valuable modalities, clinical trials and guidance, personalization, and biomarkers, all of which are essential for understanding the success of cancer immunotherapy. This innovative therapy has been investigated worldwide as the fourth line of cancer treatment after the standard treatments of surgery, chemotherapy, and radiotherapy. The progress in fundamental understanding of tumor immunology and the recent advances in clinical trials have opened new avenues with a cancer vaccine in 2010 and immunocheckpoint modulation in 2011, with their approval already granted in the United States. Today, there are no doubts, even among experts in cancer chemotherapy and radiotherapy, that the immune system plays a vital role in tumor eradication. Following American approval, many clinical trials of cancer immunotherapy are being conducted. With this book the reader will readily understand the paradigm shift in cancer treatment and will realize the importance of cancer immunotherapy. The great value of immunotherapy will be obvious, not only for tumor shrinkage but for prolonging patient survival.
650 0 $a Cancer $x Immunotherapy. $3 201873
650 1 4 $a Medicine & Public Health. $3 273799
650 2 4 $a Oncology. $3 195181
650 2 4 $a Cancer Research. $3 273660
650 2 4 $a Immunology. $3 189152
700 1 $a Yamaguchi, Yoshiyuki. $3 741095
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer eBooks
856 4 0 $u http://dx.doi.org/10.1007/978-4-431-55031-0
950 $a Medicine (Springer-11650)